In the face of challenges such as cost reduction, regulatory complexities, and the need for innovation, the life sciences industry is aggressively investing in digital technologies like generative AI, advanced analytics, automation, and cybersecurity. Enhancing R&D efficiency is crucial for accelerating the time-to-market for advanced treatments, while breakthroughs in genomics are driving personalized medicine. Life sciences companies also leverage digital solutions to strengthen their manufacturing and supply chains, ensuring agility, quality, and efficiency in delivering critical therapies. Optimizing sales and marketing strategies enhances customer engagement and market access while increasing ESG adoption reflects growing regulatory, investor, and societal expectations. To drive these transformations, life sciences enterprises collaborate with service providers for digital expertise and execution.
Both demand-side and supply-side trends are covered in our Life Sciences Digital Services 2025 Market Insights™ and Life Sciences Digital Services 2025 RadarView™, respectively. These reports present a comprehensive study of digital service providers in the life sciences industry, including top trends, analysis, and recommendations. It takes a close look at the leaders, innovators, disruptors, and challengers in this market.
We evaluated 38 service providers across three dimensions: practice maturity, partner ecosystem, and investments and innovation. Of the 38 providers, we recognized 20 that brought the most value to the market over the past 12 months.
The reports recognize service providers across four categories:
-
- Leaders: Accenture, Capgemini, Cognizant, HCLTech, Infosys, TCS, and Wipro
- Innovators: Genpact, IBM, LTIMindtree, and Tech Mahindra
- Disruptors: Birlasoft, Eviden, Hitachi Digital Services, NTT DATA, UST, Virtusa, and Zensar
- Challengers: DXC and Persistent Systems
Figure 1 below from the full report illustrates these categories:
“Enhancing R&D efficiency, leveraging genomics, and strengthening supply chains are key to advancing life sciences. As the industry consolidates, clients increasingly rely on MSP partnerships to drive innovation and growth,” said Rakesh Patro, Avasant partner.
The reports provide several findings, including the following:
-
- Life sciences enterprises use Gen AI to shorten drug development timelines by generating molecules, predicting drug-target interactions, optimizing trials, and expediting regulatory submissions
- Advances in genomics are revolutionizing healthcare by driving a shift toward personalized medicine
- Life sciences organizations are utilizing Industry 4.0, real-time analytics, AI, and advanced supply chain strategies to drive continuous manufacturing, small-batch production for advanced therapies, and greater transparency
- Optimized sales and marketing strategies are helping strengthen customer engagement and expanding market access
- Regulatory pressures, investor expectations, and a commitment to sustainability and health equity are driving ESG adoption
“Gen AI is revolutionizing life sciences by designing drug molecules, repurposing drugs, and enhancing the patient experience by driving adherence among patients and providing crucial knowledge about the medications they consume,” said Eratha Poongkuntran, research leader with Avasant.
The RadarView also features detailed profiles of 20 service providers, along with their solutions, offerings, and experience in assisting life sciences enterprises in their digital transformation journeys.
This Research Byte provides a brief overview of Avasant’s Life Sciences Digital Services 2025 Market Insights™ and Life Sciences Digital Services 2025 RadarView™ (click for pricing).